J Korean Assoc Oral Maxillofac Surg.  2016 Apr;42(2):84-89. 10.5125/jkaoms.2016.42.2.84.

Comparison of ondansetron and granisetron for antiemetic prophylaxis in maxillofacial surgery patients receiving general anesthesia: a prospective, randomised, and double blind study

• Savant K
• Khandeparker RVS
• Berwal V
• Khandeparker PV
• Jain H

• KMID: 2351730
• DOI: http://doi.org/10.5125/jkaoms.2016.42.2.84

Abstract

OBJECTIVES
To compare the efficacy of intravenous ondansetron (4 mg, 2 mL) and granisetron (2 mg, 2 mL) for preventing postoperative nausea and vomiting (PONV) in patients during oral and maxillofacial surgical procedures under general anesthesia.
MATERIALS AND METHODS
A prospective, randomized, and double blind clinical study was carried out with 60 patients undergoing oral and maxillofacial surgical procedures under general anesthesia. Patients were divided into two groups of 30 individuals each. Approximately two minutes before induction of general anesthesia, each patient received either 4 mg (2 mL) ondansetron or 2 mg (2 mL) granisetron intravenously in a double blind manner. Balanced anesthetic technique was used for all patients. Patients were assessed for episodes of nausea, retching, vomiting, and the need for rescue antiemetic at intervals of 0-2, 3, 6, 12, and 24 hours after surgery. Incidence of complete response and adverse effects were assessed at 24 hours postoperatively. Data was tabulated and subjected to statistical analysis using the chi-square test, unpaired t-test, or the Mann-Whitney U-test as appropriate. A P-value less than 0.05 was considered statistically significant.
RESULTS
There was no statistically significant difference between the two groups for incidence of PONV or the need for rescue antiemetic. Both study drugs were well tolerated with minimum adverse effects; the most common adverse effect was headache. The overall incidence of complete response in the granisetron group (86.7%) was significantly higher than the ondansetron group (60.0%).
CONCLUSION
Granisetron at an intravenous dose of 2 mg was found to be safe, well tolerated, and more effective by increasing the incidence of complete response compared to 4 mg intravenous ondansetron when used for antiemetic prophylaxis in maxillofacial surgery patients receiving general anesthesia. Benefits of granisetron include high receptor specificity and high potency, which make it a valuable alternative to ondansetron.

Keyword

Anesthesia; General; Granisetron; Ondansetron; Postoperative nausea and vomiting

MeSH Terms

Anesthesia
Anesthesia, General*
Double-Blind Method*
Granisetron*
Headache
Humans
Incidence
Nausea
Ondansetron*
Postoperative Nausea and Vomiting
Prospective Studies*
Sensitivity and Specificity
Surgery, Oral*
Vomiting
Granisetron
Ondansetron

Reference

1. Talesh KT, Motamedi MH, Kahnamouii S. Comparison of ondansetron and metoclopramide antiemetic prophylaxis in maxillofacial surgery patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011; 111:275–277. PMID: 20674417.

2. Bhattacharya D, Banerjee A. Comparison of ondansetron and granisetron for prevention of nausea and vomiting following day care gynaecological laparoscopy. Indian J Anaesth. 2003; 47:279–282.

3. Leeser J, Lip H. Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist. Anesth Analg. 1991; 72:751–755. PMID: 1827966.

4. McKenzie R, Kovac A, O'Connor T, Duncalf D, Angel J, Gratz I, et al. Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. Anesthesiology. 1993; 78:21–28. PMID: 8424561.

5. Honkavaara P. Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. Br J Anaesth. 1996; 76:316–318. PMID: 8777119.

6. Dershwitz M, Conant JA, Chang Y, Rosow CE, Connors PM. A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting. J Clin Anesth. 1998; 10:314–320. PMID: 9667348.

7. Liberman MA, Howe S, Lane M. Ondansetron versus placebo for prophylaxis of nausea and vomiting in patients undergoing ambulatory laparoscopic cholecystectomy. Am J Surg. 2000; 179:60–62. PMID: 10737581.

8. Rodrigo C, Campbell R, Chow J, Tong A. The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery. J Oral Maxillofac Surg. 1996; 54:1171–1175. PMID: 8859234.

9. Wagley C, Hackett C, Haug RH. The effect of preoperative ondansetron on the incidence of postoperative nausea and vomiting in patients undergoing outpatient dentoalveolar surgery and general anesthesia. J Oral Maxillofac Surg. 1999; 57:1195–1200. PMID: 10513865.

10. Kovac AL. The prophylactic treatment of postoperative nausea and vomiting in oral and maxillofacial surgery. J Oral Maxillofac Surg. 2005; 63:1531–1535. PMID: 16182924.

11. Kovac AL, O'Connor TA, Pearman MH, Kekoler LJ, Edmondson D, Baughman VL, et al. Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled multicenter trial. J Clin Anesth. 1999; 11:453–459. PMID: 10526822.

12. Smith HS, Cox LR, Smith EJ. 5-HT3 receptor antagonists for the treatment of nausea/vomiting. Ann Palliat Med. 2012; 1:115–120. PMID: 25841471.

13. Pasricha PJ. Prokinetic agents, antiemetics, and agents used in irritable bowel syndrome. In : Goodman LS, Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill;2001. p. 1021–1036.

14. Facts and Comparisons (Firm). Drug facts and comparisons 2003. 57th ed. St. Louis: Facts and Comparisons;2003.

15. Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist. 2004; 9:673–686. PMID: 15561811.

16. Fujii Y, Saitoh Y, Tanaka H, Toyooka H. Comparison of ramosetron and granisetron for preventing postoperative nausea and vomiting after gynecologic surgery. Anesth Analg. 1999; 89:476–479. PMID: 10439770.

17. Kovac AL, Pearman MH, Khalil SN, Scuderi PE, Joslyn AF, Prillaman BA, et al. S3A-379 Study Group. Ondansetron prevents postoperative emesis in male outpatients. J Clin Anesth. 1996; 8:644–651. PMID: 8982892.

18. Fujii Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. Can J Anaesth. 1994; 41:794–797. PMID: 7954995.

19. Mikawa K, Takao Y, Nishina K, Maekawa N, Obara H. The antiemetic efficacy of prophylactic granisetron in gynecologic surgery. Anesth Analg. 1995; 80:970–974. PMID: 7726441.

20. Fujii Y, Toyooka H, Tanaka H. Granisetron reduces the incidence of nausea and vomiting after middle ear surgery. Br J Anaesth. 1997; 79:539–540. PMID: 9389277.

21. Figueredo ED, Canosa LG. Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis. J Clin Anesth. 1998; 10:211–221. PMID: 9603591.

22. Bestas A, Onal SA, Bayar MK, Yildirim A, Aygen E. Effects of ondansetron and granisetron on postoperative nausea and vomiting in adult patients undergoing laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled clinical trial. Curr Ther Res Clin Exp. 2007; 68:303–312. PMID: 24692762.

23. Naguib M, el Bakry AK, Khoshim MH, Channa AB, el Gammal M, el Gammal K, et al. Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, doubleblind comparison with placebo. Can J Anaesth. 1996; 43:226–231. PMID: 8829860.